Literature DB >> 16137613

Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor.

B Vander Cruyssen1, I Peene, T Cantaert, I E A Hoffman, L De Rycke, E M Veys, F De Keyser.   

Abstract

Anti-citrullinated protein/peptide antibodies (ACPA) are highly specific and sensitive markers for rheumatoid arthritis (RA). For instance, for the anti-CCP2 assay, sensitivities ranging from 55% to 80% and specificities ranging from 90% to 98% have been reported. Despite their high specificity, recent reports have suggested that ACPA may be found in some patients with other rheumatic autoimmune diseases, including psoriatic arthritis, systemic lupus erythematosus and Sjögren's syndrome. Also, the differences between the classical rheumatoid factor (RF) and ACPA, as well as the complementarity between both tests have recently been demonstrated more clearly. Indeed, both antibody systems have a different association with specific RA features like extra-articular manifestations, a different association with the HLA shared epitope and, behave differently following anti-TNF therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16137613     DOI: 10.1016/j.autrev.2005.04.018

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  25 in total

1.  Autoreactive T cells specific for insulin B:11-23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes.

Authors:  Junbao Yang; I-Ting Chow; Tomasz Sosinowski; Nadia Torres-Chinn; Carla J Greenbaum; Eddie A James; John W Kappler; Howard W Davidson; William W Kwok
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

Review 2.  The clinical significance of posttranslational modification of autoantigens.

Authors:  Maria G Zavala-Cerna; Erika A Martínez-García; Olivia Torres-Bugarín; Benjamín Rubio-Jurado; Carlos Riebeling; Arnulfo Nava
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

3.  Anti-cyclic citrullinated peptide and rheumatoid factor in patients with chronic hepatitis B and hepatitis B carriers.

Authors:  Ediz Dalkılıç; Mustafa Ferhat Öksüz; Ayşe Nur Tufan; Aysun Özbek; Ali Nizamoğlu; Mürside Esra Dolarslan; Belkıs Nihan Coşkun; Yavuz Pehlivan
Journal:  Eur J Rheumatol       Date:  2015-03-31

4.  Antibodies to a new viral citrullinated peptide, VCP2: fine specificity and correlation with anti-cyclic citrullinated peptide (CCP) and anti-VCP1 antibodies.

Authors:  F Pratesi; C Tommasi; C Anzilotti; I Puxeddu; E Sardano; G Di Colo; P Migliorini
Journal:  Clin Exp Immunol       Date:  2011-03-17       Impact factor: 4.330

5.  Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan.

Authors:  Kumi Shidara; Eisuke Inoue; Daisuke Hoshi; Eri Sato; Ayako Nakajima; Shigeki Momohara; Atsuo Taniguchi; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2010-11-27       Impact factor: 2.631

6.  Loss of SH3 domain-binding protein 2 function suppresses bone destruction in tumor necrosis factor-driven and collagen-induced arthritis in mice.

Authors:  Tomoyuki Mukai; Richard Gallant; Shu Ishida; Mizuho Kittaka; Teruhito Yoshitaka; David A Fox; Yoshitaka Morita; Keiichiro Nishida; Robert Rottapel; Yasuyoshi Ueki
Journal:  Arthritis Rheumatol       Date:  2015-03       Impact factor: 10.995

7.  High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.

Authors:  Francesca Bobbio-Pallavicini; Roberto Caporali; Claudia Alpini; Stefano Avalle; Oscar M Epis; Catherine Klersy; Carlomaurizio Montecucco
Journal:  Ann Rheum Dis       Date:  2006-11-01       Impact factor: 19.103

8.  Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis.

Authors:  Marja-Kaisa Koivula; Markku Heliövaara; Jarmo Ramberg; Paul Knekt; Harri Rissanen; Timo Palosuo; Juha Risteli
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

9.  Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis.

Authors:  N Inanc; E Dalkilic; S Kamali; E Kasapoglu-Günal; Y Elbir; H Direskeneli; M Inanc
Journal:  Clin Rheumatol       Date:  2006-03-15       Impact factor: 2.980

10.  A broad screen for targets of immune complexes decorating arthritic joints highlights deposition of nucleosomes in rheumatoid arthritis.

Authors:  Paul A Monach; Wolfgang Hueber; Benedikt Kessler; Beren H Tomooka; Maya BenBarak; Barry P Simmons; John Wright; Thomas S Thornhill; Marc Monestier; Hidde Ploegh; William H Robinson; Diane Mathis; Christophe Benoist
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.